Liu ZY, Tian L, Sun XY, Liu ZS, Hao LJ, Shen WW, Gao YQ, Zhai HH. Development and validation of a risk prediction score for the severity of acute hypertriglyceridemic pancreatitis in Chinese patients. World J Gastroenterol 2022; 28(33): 4846-4860 [PMID: 36156930 DOI: 10.3748/wjg.v28.i33.4846]
Corresponding Author of This Article
Hui-Hong Zhai, MD, PhD, Chief Physician, Doctor, Professor, Department of Gastroenterology, Xuanwu Hospital, Capital Medical University, No. 45 Changchun Street, Beijing 100053, China. zhaihuihong@263.net
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 7, 2022; 28(33): 4846-4860 Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4846
Table 1 Demographic and clinical characteristics of patients in the non-severe acute pancreatitis and severe acute pancreatitis groups
Patient characteristics
All (n = 243)
Non-SAP (n = 181)
SAP (n = 62)
P value
Demographic variables
Sex, n (%)
0.297
Male
188 (77.37)
143 (79.00)
45 (72.60)
Female
55 (22.63)
38 (21.00)
17 (27.40)
Age (yr)
40.12 ± 10.12
39.60 ± 10.10
41.60 ± 10.20
0.190
BMI (kg/m2)
28.27 ± 4.25
28.10 ± 4.00
28.70 ± 4.90
0.367
Medical history
Diabetes, n (%)
0.648
Yes
139 (57.20)
102 (56.40)
37 (59.70)
No
104 (42.80)
79 (43.65)
25 (40.30)
Hypertension, n (%)
0.164
Yes
59 (24.28)
48 (26.50)
11 (17.70)
No
184 (75.72)
133 (73.50)
51 (82.30)
Hyperlipidemia, n (%)
0.250
Yes
152 (62.55)
64 (35.40)
27 (43.50)
No
91 (37.45)
64 (35.40)
27 (43.50)
Fatty liver, n (%)
0.073
Yes
185 (76.13)
143 (79.00)
42 (67.70)
No
58 (23.87)
38 (21.00)
20 (32.30)
Drinking, n (%)
0.483
Yes
120 (49.38)
87 (48.10)
33 (53.20)
No
123 (50.62)
94 (51.90)
29 (46.80)
Smoking, n (%)
0.386
Yes
133 (54.73)
102 (56.40)
31 (50.00)
No
110 (45.27)
79 (43.60)
31 (50.00)
Clinical signs
HR (bpm)
96.14 ± 18.17
92.23 ± 16.30
107.58 ± 18.65
< 0.001
R (bpm)
21.66 ± 5.33
20.47 ± 4.38
25.27 ± 6.21
< 0.001
SBP (mmHg)
133.50 ± 17.52
133.51 ± 16.56
133.48 ± 20.21
0.992
DBP (mmHg)
81.13 ± 12.03
80.85 ± 11.28
81.92 ± 14.08
0.548
Non-SAP (n = 181, 74.49%)
SAP (n = 62, 25.51%)
Laboratory findings
WBC (× 109/L)
12.53 ± 3.86
11.96 ± 3.63
14.41 ± 3.97
< 0.001
NLR
9.94 ± 7.27
8.82 ± 6.98
13.19 ± 7.15
< 0.001
RDW (fL)
12.87 ± 0.72
12.80 ± 0.69
13.08 ± 0.78
0.009
PLT (× 109/L)
218.91 ± 61.98
216.09 ± 57.99
227.15 ± 72.30
0.226
MPV (fL)
10.75 ± 1.05
10.68 ± 1.01
10.95 ± 1.14
0.074
PDW (fL)
12.66 ± 2.22
12.47 ± 2.09
13.23 ± 2.47
0.018
TC (mmol/L)
10.15 ± 4.11
9.54 ± 3.62
11.94 ± 4.92
< 0.001
TG (mmol/L)
21.08 ± 7.50
20.17 ± 7.31
23.75 ± 7.49
0.001
H/L ratio
0.96 ± 1.36
0.96 ± 1.36
0.97 ± 1.36
0.946
ApoA1 (g/L)
1.02 ± 0.35
1.11 ± 0.34
0.75 ± 0.23
< 0.001
TBIL (μmol/L)
14.16 ± 8.29
13.81 ± 7.11
15.16 ± 11.03
0.987
AST (U/L)
29.78 ± 17.41
27.40 ± 13.03
36.76 ± 25.20
< 0.001
ALT (U/L)
31.04 ± 28.70
30.80 ± 29.94
31.73 ± 24.94
0.826
ALP (U/L)
73.91 ± 25.30
73.59 ± 22.70
74.84 ± 31.88
0.737
ALB (g/L)
41.57 ± 5.91
42.22 ± 5.53
39.66 ± 6.58
0.003
BUN mmol/L
4.32 ± 2.03
4.05 ± 1.39
5.10 ± 3.12
< 0.001
Cr (μmol/L)
62.62 ± 42.98
56.64 ± 15.83
80.10 ± 78.56
< 0.001
fT3 (pmol/L)
1.97 ± 0.37
1.99 ± 0.36
1.91 ± 0.41
0.134
CRP (mg/L)
160.20 ± 127.36
133.55 ± 112.64
237.99 ± 136.59
< 0.001
PCT (ng/mL)
0.80 ± 1.93
0.59 ± 1.72
1.42 ± 2.35
0.003
ESR (mm/h)
42.57 ± 24.76
40.71 ± 25.10
47.99 ± 23.06
0.045
Na (mmol/L)
133.97 ± 4.29
134.28 ± 4.09
133.07 ± 4.76
0.054
K (mmol/L)
4.02 ± 0.46
3.97 ± 0.35
4.19 ± 0.67
0.080
Ca2+ (mmol/L)
2.13 ± 0.26
2.19 ± 0.18
1.96 ± 0.36
< 0.001
PT (s)
13.26 ± 0.98
13.12 ± 0.84
13.68 ± 1.21
< 0.001
APTT (s)
37.82 ± 5.28
37.35 ± 5.14
39.22 ± 5.45
0.016
TT (s)
15.07 ± 1.10
15.08 ± 1.09
15.05 ± 1.13
0.823
FIB (g/L)
5.70 ± 2.21
5.41 ± 2.10
6.56 ± 2.32
< 0.001
D-dimer (μg/L)
1.34 ± 1.83
0.94 ± 0.98
2.51 ± 2.94
< 0.001
Imaging results
Pleural effusion, n (%)
< 0.001
Yes
69 (28.40)
23 (12.71)
46 (74.19)
No
174 (71.61)
158 (87.30)
16 (25.81)
Table 2 Univariable and multivariable logistic regression analyses of predictive factors for severe acute pancreatitis in all subjects
Variables
Univariable regression
Multivariable regression
OR (95%CI)
P value
OR (95%CI)
P value
Age
1.02 (0.99-1.05)
0.190
1.07 (1.01-1.14)
0.033
BMI (kg/m2)
1.03 (0.96-1.10)
0.366
1.08 (0.94-1.24)
0.278
Hypertension
No
1.00
1.00
Yes
0.60 (0.29-1.24)
0.167
1.02 (0.99-1.06)
0.201
Diabetes
No
1.00
1.00
Yes
1.15 (0.64-2.06)
0.648
1.27 (0.38-4.24)
0.693
HR (bpm)
1.05 (1.03-1.07)
< 0.0001
1.02 (0.99-1.06)
0.201
RR (bpm)
1.20 (1.12-1.28)
< 0.0001
1.12 (0.99-1.26)
0.068
TG (mmol/L)
< 11.3
1.00
1.00
11.3-22.6
2.06 (0.57-7.49)
0.273
4.20 (0.40-44.25)
0.232
≥ 22.6
3.43 (0.96-12.20)
0.057
5.95 (0.56-62.75)
0.138
ApoA1 (g/L)
0.01 (0.00-0.05)
< 0.0001
0.02 (0.00-0.12)
< 0.0001
Cr (μmol/L)
1.02 (1.01-1.03)
0.002
1.01 (0.99-1.02)
0.458
Bun (μmol/L)
1.27 (1.10-1.48)
0.001
1.29 (0.92-1.81)
0.145
WBC (× 109/L)
1.18 (1.09-1.28)
< 0.0001
1.08 (0.95-1.24)
0.248
Ca2+ (mmol/L)
0.02 (0.01-0.09)
< 0.0001
0.11 (0.01-1.02)
0.040
D-dimer (μg/L)
1.69 (1.35-2.12)
< 0.0001
1.24 (0.94-1.63)
0.122
Pleural effusion
19.75 (9.64-40.48)
< 0.0001
15.62 (5.05-48.24)
< 0.0001
Table 3 Comparison of diagnostic performance for predicting severe acute pancreatitis between the AAP and other existing clinical scores
Variables
ΔAUC
95%CI
Z statistic
P value
AAP-APACHE II
0.122
0.057-0.187
3.661
0.000
AAP-BISAP
0.076
0.007-0.198
3.839
0.000
AAP-MCTSI
0.098
0.027-0.305
3.111
0.002
AAP-Ranson
0.104
0.048-0.159
3.670
0.000
AAP-EASY
0.122
0.056-0.188
3.606
0.000
Table 4 Diagnostic performance of the integrated discrimination improvement between the AAP and other clinical scores
Variables
IDI
SE
95%CI
Z statistic
P value
AAP-APACHE-II
0.201
0.077
0.050-0.352
2.601
0.009
AAP-BISAP
0.095
0.052
0.037-0.115
1.828
0.068
AAP-MCTSI
0.166
0.071
0.036-0.160
2.339
0.019
AAP-Ranson
0.216
0.063
0.093-0.338
3.444
0.001
AAP-EASY
0.205
0.082
0.045-0.365
2.513
0.012
Table 5 The relationship between risk stratification and clinical parameters
Low-risk group (n = 158)
High-risk group (n = 85)
P value
Local complications
APFC
43 (27.22%)
68 (80.00%)
< 0.001
PPC
3 (1.90%)
10 (11.77%)
0.001
ANC
3 (1.90%)
22 (25.88%)
< 0.001
WON
0 (0.00%)
4 (4.71%)
0.014
Systemic complications
SIRS
92 (58.23%)
72 (84.71%)
< 0.001
Respiratory failure
29 (18.35%)
59 (69.41%)
< 0.001
Renal failure
0 (0.00%)
13 (15.29%)
< 0.001
Cardiovascular failure
2 (1.27%)
5 (5.88%)
0.040
Clinical Scoring Systems
Ranson ≥ 3
28 (17.72%)
53 (62.35%)
< 0.001
BISAP ≥ 3
0 (0.00%)
4 (4.71%)
0.014
MCTSI ≥ 4
15 (9.49%)
53 (62.35%)
< 0.001
APACHE-II ≥ 8
73 (46.20%)
68 (80.00%)
< 0.001
CRP ≥ 190
42 (26.58%)
44 (51.77%)
< 0.001
Hospital day, days
13.51 ± 5.45
20.04 ± 8.14
< 0.001
Citation: Liu ZY, Tian L, Sun XY, Liu ZS, Hao LJ, Shen WW, Gao YQ, Zhai HH. Development and validation of a risk prediction score for the severity of acute hypertriglyceridemic pancreatitis in Chinese patients. World J Gastroenterol 2022; 28(33): 4846-4860